Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress

Cerenome posts first CNSide diagnostic revenue but faces rising losses and cash pressure.

What the company is saying

Cerenome frames this quarter as a commercial inflection point, highlighting the recognition of $0.7 million in net diagnostic revenue from CNSide and the start of commercial payments in October. The company emphasizes payer coverage expansion, now claiming approximately 190 million covered lives, and points to the Aetna agreement as the first national CNSide payer contract covering both tumor cell enumeration and molecular profiling. Management, led by CEO Marc H. Hedrick, M.D., and newly appointed Chief Business Officer Ron Andrews, underscores ongoing clinical progress, including completed enrollment in the Phase 2 ReSPECT-GBM trial and interim safety data from the ReSPECT-LM study. The narrative stresses future milestones: Medicare reimbursement targeted for the first half of 2027, topline clinical data expected mid-2027, and further commercial rollout of CNSide. The tone is confident but acknowledges the need for continued execution, especially as cost pressures and losses mount. The company also details recent financing activities, including a $20 million facility and $3.8 million raised post-quarter, to address liquidity needs.

What the data suggests

Financial results show Cerenome recognized $0.7 million in net diagnostic revenue for Q3 2026, with gross billings of $1.55 million, indicating significant payer adjustments and price concessions. Cash, cash equivalents, and investments fell sharply from $8.6 million at June 30 to $4.9 million at September 30, 2026, while current liabilities rose to $13.1 million, exceeding current assets of $8.1 million. Operating loss widened to $7.5 million from $4.5 million year-over-year, and net loss more than doubled to $8.7 million ($1.14 per share). Selling, general, and administrative expenses increased to $5.2 million from $3.4 million, while R&D expenses declined slightly. The company secured a $20 million senior secured financing facility and raised $3.8 million via equity, but the cash burn rate remains high. Clinical progress is real—Phase 2 ReSPECT-GBM enrollment is complete and interim safety data from ReSPECT-LM show no dose-limiting toxicities in the first 10 patients—but efficacy data and commercial traction are not yet demonstrated at scale. The company’s claims of payer coverage expansion are factual, but actual revenue remains modest relative to the addressable market. Grants of $17.6 million (CPRIT) and $3 million (DoD) support clinical programs, but do not offset the overall cash burn.

Analysis

The announcement provides a factual and detailed account of Cerenome's financials, including the first quarter of CNSide diagnostic revenue ($0.7M), cash position, and operating/net losses. Several realized milestones are disclosed, such as payer coverage expansion and clinical trial enrollment completion. However, the narrative emphasizes future benefits—Medicare reimbursement, topline data in 2027, and ongoing dose escalation—without supporting these projections with operational or clinical data. The company highlights a large capital raise ($20M facility, $3.8M equity) but remains deeply loss-making, with current liabilities exceeding current assets and no immediate path to profitability. While the tone is measured, the gap between the scale of future ambitions and current financial/operational traction introduces moderate hype. The majority of forward-looking claims are plausible but not yet realized, and the capital intensity is high relative to near-term revenue.

Risk flags

• ●Liquidity risk is acute: cash, cash equivalents, and investments fell to $4.9 million at September 30, 2026, while current liabilities reached $13.1 million, indicating a need for continued external financing to sustain operations.
• ●Commercialization risk remains high: despite payer agreements covering 190 million lives, actual net diagnostic revenue was only $0.7 million for the quarter, suggesting slow uptake or reimbursement delays.
• ●Clinical execution risk persists: topline data for key trials (ReSPECT-GBM and ReSPECT-LM) are not expected until mid-2027, and current disclosures provide no efficacy results, only interim safety data in a small cohort.
• ●Cost structure risk is evident: selling, general, and administrative expenses rose to $5.2 million, outpacing revenue and contributing to a widening operating loss, raising questions about scalability and path to profitability.
• ●Forward-looking claims on Medicare reimbursement and expanded adoption are not yet supported by concrete operational or financial evidence, making future milestones uncertain.

Bottom line

Cerenome’s first quarter of CNSide diagnostic revenue marks initial commercial progress, but the scale—$0.7 million net—remains small against a backdrop of rising losses and shrinking cash reserves. The company is aggressively pursuing payer coverage and clinical development, but actual adoption and reimbursement are lagging the addressable market. Cash burn is high, with current liabilities now exceeding current assets, and ongoing operations depend on recently secured financing and further capital raises. Near-term catalysts, such as Medicare reimbursement and topline clinical data, are months away and carry execution risk. For investors, the main takeaway is that while the platform and pipeline are advancing, the company’s financial runway is short and commercial traction must accelerate to justify the current strategy. Evidence of increasing test volumes, payer collections, and positive clinical outcomes will be critical for future re-rating.

Announcement summary

(NASDAQ: CNSY) Cerenome, Inc. reported financial results for the third quarter ended September 30, 2026, and provided a business update. The company recognized its first quarter of CNSide diagnostic revenue, with commercial payments beginning in October. Approximately $1.55 million in gross billings at list prices were submitted for CNSide, and $0.7 million in net diagnostic revenue was recognized in the quarter after estimated payer adjustments and price concessions. As of September 30, 2026, cash, cash equivalents, and investments totaled $4.9 million, compared to $8.6 million as of June 30, 2026. The company closed a senior secured financing facility up to $20 million with royalty-based repayments in September. Subsequent to quarter end, $3.8 million was raised under the Equity Distribution Agreement. Total revenue for the quarter was $0.7 million, all from net diagnostic revenue. Cost of revenue was $0.9 million. Research and development expense was $2.1 million, compared with $2.4 million a year earlier. Selling, general and administrative expense was $5.2 million, compared with $3.4 million a year earlier. Operating loss was $7.5 million, compared with $4.5 million a year earlier. Net loss was $8.7 million, or $1.14 per share, compared with $4.4 million, or $1.03 per share, a year earlier. The company rebranded from Plus Therapeutics to Cerenome and began trading under the symbol CNSY on August 3, 2026. Ron Andrews was appointed Chief Business Officer in November and continues to serve on the Board of Directors. The company expanded contracted coverage for CNSide through agreements with Medical Mutual, Health Care Service Corporation, Blue Cross Blue Shield of Michigan, Florida Blue, and Aetna, with the Aetna agreement effective November 1 as the first national CNSide payer agreement to include both tumor cell enumeration and molecular profiling. The aggregate contracted footprint now represents approximately 190 million covered lives. Cerenome entered a collaboration with Genomic Testing Cooperative to add DNA and RNA profiling to CNSide. XiFin was selected for revenue cycle management and clearinghouse services. Samantha Fowlkes was appointed Vice President and Head of Commercial Sales for CNSide Diagnostics. The company is on track for Medicare reimbursement in the first half of 2027 and is pursuing a coverage determination from Novitas Solutions. CNSide CSF Molecular Profile tests were launched for solid tumors and hematologic malignancies, available to order beginning October 12. In therapeutics, the company completed enrollment in the Phase 2 ReSPECT-GBM study in recurrent glioblastoma in October and presented interim Phase 1 ReSPECT-LM (multi-dose) findings at the Society of Neuro Oncology Annual meeting in November. The first 10 patients in ReSPECT-LM received repeated intraventricular doses of REYOBIQ with no dose-limiting toxicities or treatment discontinuations due to adverse events. Dose escalation is ongoing to identify a recommended multiple-dose regimen for a follow-on randomized study. Investigators reported preclinical data at the Rivkin Ovarian Cancer Research Symposium in October showing the active agent in REYOBIQ was associated with a new mechanism of action and enhanced antitumor activity when combined with anti-PD-1 checkpoint blockade. The ReSPECT-LM program's pharmacokinetic, dosimetry, and safety observations were presented at the SNO/ASCO CNS Metastases Conference in August. A separate presentation examined the potential health economic impact of earlier detection of leptomeningeal metastases using CNSide. The ReSPECT-LM trial is funded by a three-year $17.6 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT), and the ReSPECT-PBC clinical trial for pediatric brain cancer is supported by a $3 million grant from the U.S. Department of Defense's Peer Reviewed Cancer Research Program. The company will host a conference call and webcast on November 16, 2026, at 8:30 a.m. ET to discuss third quarter results and provide a business update.

Disagree with this article?